FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5)

FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5)

  • April 2015 •
  • Report ID: 3090959 •
  • Format: PDF

What market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to availability to reimbursement factors, FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5) provides insights that can help develop, shape and refine your brand strategies. Also Available is FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US). To purchase both and receive a free US/EU5 Comparison report, contact FirstWord.

Based on data gained from proprietary analytics, gain visibility into why physicians are prescribing, or not, certain drugs to treat T2DM. This information allows you to act strategically, drive market share gains and improve competitiveness for your brand.

Get Answers to Key Questions

How does product pricing, availability and reimbursement affect a physician’s decision to prescribe one product over another?
What T2DM drug treatments are gaining share and which ones are losing share due to these barriers?
In the T2DM market, what percentage of prescriptions are influenced by barriers, what are the barriers experienced and the volume of prescriptions these barriers represent?

Insight and Analysis Provided

Byetta (exenatide)
Onglyza (saxagliptin)
Farxiga (dapagliflozin)
Johnson & Johnson
Invokana (canagliflozin)
Merck & Co.
Januvia (sitagliptin)
Novo Nordisk
Victoza (liraglutide)
Levemir (Insulin detemir)
Lantus (Insulin glargine)

Key Issues Explored

The amount of share your brand gains and loses due to specific market barriers.

The user mix for your brand, plus doctors who are not current users but would consider using it.

The percentage of prescriptions influenced by barriers, the barriers experienced and the volume of scripts these barriers represent.


Sample Distribution
A mixed total of 150: 66 endocrinologists and 84 general practitioners in France, Italy, Spain, Germany, UK

Interviewing Methodology
Data collected via a 10-minute questionnaire.

Screening Criteria

About FirstWord Reports

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at